Among patients with ACS who undergo PCI, a prasugrel-based strategy is superior to one using ticagrelor in terms of all-cause death, MI, and stroke at 12 months, according to a prespecified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback